Literature DB >> 8318425

Strong HLA-DR expression in large bowel carcinomas is associated with good prognosis.

S N Andersen1, T O Rognum, E Lund, G I Meling, S Hauge.   

Abstract

One hundred large bowel carcinomas operated on between 1978 and 1982 were studied immunohistochemically with regard to expression of HLA-DR antigens. Three sections from each tumour were investigated by a semiquantitative scoring system, and a mean score for each patient established. Based on this scoring system, the tumours were divided into three groups: 0; 0.1-1.0; and > 1.0. All patients were followed until death (n = 68) or until June 1, 1992, and all cancer-specific deaths (n = 56) have been recorded. Analysis of survival in the whole patient group showed significant difference between the three levels of tumour HLA-DR expression (P = 0.006); patients who had tumours with strong HLA-DR expression showing the best survival. In a stratified analysis after Dukes' stages there was still a significant difference (P > 0.001) between the three levels of HLA-DR staining intensity. After a multiple regression analysis (Cox) with correction for different variables, the HLA-DR expression maintained its significance as a risk factor. To our knowledge this is the first time a relationship between intensity of tumour DR expression and survival has been shown in large bowel carcinoma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8318425      PMCID: PMC1968312          DOI: 10.1038/bjc.1993.290

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  36 in total

1.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

2.  Anomolous expression of HLA-DR antigens on human colorectal cancer cells.

Authors:  A S Daar; S V Fuggle; A Ting; J W Fabre
Journal:  J Immunol       Date:  1982-08       Impact factor: 5.422

3.  Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer.

Authors:  H J Wanebo; B Rao; C M Pinsky; R G Hoffman; M Stearns; M K Schwartz; H F Oettgen
Journal:  N Engl J Med       Date:  1978-08-31       Impact factor: 91.245

Review 4.  [Pathologico-anatomical evaluation of colorectal cancer from a prognostic viewpoint].

Authors:  W Remmele; M Heine
Journal:  Med Welt       Date:  1981-05-15

5.  Cancer of the colon: the influence of the no-touch isolation technic on survival rates.

Authors:  R B Turnbull; K Kyle; F R Watson; J Spratt
Journal:  Ann Surg       Date:  1967-09       Impact factor: 12.969

6.  The clonal evolution of tumor cell populations.

Authors:  P C Nowell
Journal:  Science       Date:  1976-10-01       Impact factor: 47.728

7.  DNA distribution in human colon carcinomas and its relationship to clinical behavior.

Authors:  R C Wolley; K Schreiber; L G Koss; M Karas; A Sherman
Journal:  J Natl Cancer Inst       Date:  1982-07       Impact factor: 13.506

8.  The membrane antigens of human colorectal cancer cells: demonstration with monoclonal antibodies of heterogeneity within and between tumours and of anomalous expression of HLA-DR.

Authors:  A S Daar; J W Fabre
Journal:  Eur J Cancer Clin Oncol       Date:  1983-02

9.  Fluorescence staining of gastric mucosa. A study with special reference to parietal cells.

Authors:  R Stave; P Brandtzaeg
Journal:  Scand J Gastroenterol       Date:  1977       Impact factor: 2.423

10.  The spread of rectal cancer and its effect on prognosis.

Authors:  C E DUKES; H J BUSSEY
Journal:  Br J Cancer       Date:  1958-09       Impact factor: 7.640

View more
  17 in total

1.  Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer.

Authors:  I Saeterdal; J Bjørheim; K Lislerud; M K Gjertsen; I K Bukholm; O C Olsen; J M Nesland; J A Eriksen; M Møller; A Lindblom; G Gaudernack
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

2.  Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines.

Authors:  T Rodríguez; R Méndez; A Del Campo; N Aptsiauri; J Martín; G Orozco; G Pawelec; D Schadendorf; F Ruiz-Cabello; F Garrido
Journal:  Immunogenetics       Date:  2006-12-20       Impact factor: 2.846

3.  MHC class II expression in pancreatic tumors: a link to intratumoral inflammation.

Authors:  Matthias M Gaida; Thilo Welsch; Esther Herpel; Darjus F Tschaharganeh; Lars Fischer; Peter Schirmacher; G Maria Hänsch; Frank Bergmann
Journal:  Virchows Arch       Date:  2011-11-27       Impact factor: 4.064

Review 4.  MHC heterogeneity and response of metastases to immunotherapy.

Authors:  Ignacio Algarra; Federico Garrido; Angel M Garcia-Lora
Journal:  Cancer Metastasis Rev       Date:  2021-04-15       Impact factor: 9.264

5.  Growth inhibition of a colonic adenocarcinoma cell line (HT29) by T cells specific for mutant p21 ras.

Authors:  T Gedde-Dahl; E Nilsen; E Thorsby; G Gaudernack
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

6.  Identification of an HLA-A0201-restricted CTL epitope generated by a tumor-specific frameshift mutation in a coding microsatellite of the OGT gene.

Authors:  Eva Ripberger; Michael Linnebacher; Yvette Schwitalle; Johannes Gebert; Magnus von Knebel Doeberitz
Journal:  J Clin Immunol       Date:  2003-09       Impact factor: 8.317

7.  Lymphocyte subset infiltration patterns and HLA antigen status in colorectal carcinomas and adenomas.

Authors:  P A Jackson; M A Green; C G Marks; R J King; R Hubbard; M G Cook
Journal:  Gut       Date:  1996-01       Impact factor: 23.059

8.  Immunohistochemical expression of C-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma.

Authors:  A C Lazaris; G E Theodoropoulos; K Aroni; A Saetta; P S Davaris
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

9.  Absent in Melanoma 2 (AIM2) is an important mediator of interferon-dependent and -independent HLA-DRA and HLA-DRB gene expression in colorectal cancers.

Authors:  J Lee; L Li; N Gretz; J Gebert; S Dihlmann
Journal:  Oncogene       Date:  2011-08-01       Impact factor: 9.867

10.  K-ras mutations and HLA-DR expression in large bowel adenomas.

Authors:  S Norheim Andersen; J Breivik; T Løvig; G I Meling; G Gaudernack; O P Clausen; A Schjölberg; O Fausa; F Langmark; E Lund; T O Rognum
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.